TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer 2024; 201:113588.
Feb 2, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Feb 2, 2024
Eur J Cancer 2024; 201:113588
Colombo Ilaria, Koster Kira-Lee, Holer Lisa, Haefliger Simon, Rabaglio-Poretti Manuela, Bastian Sara, Schwitter Michael, Eckhardt Katrin, Hayoz Stefanie, Mc Laughlin Anna M, Kloft Charlotte, Klose Marian, Halbherr Stefan, Baumgartner Christian, Sessa Cristiana, Stathis Anastasios, Hess Dagmar, Jörger Markus
more
